# Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors

> **NCT00276575** · PHASE1 · COMPLETED · sponsor: **Herbert Hurwitz, MD** · enrollment: 65 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** bevacizumab
- **DRUG:** erlotinib hydrochloride
- **DRUG:** everolimus

## Key facts

- **NCT ID:** NCT00276575
- **Lead sponsor:** Herbert Hurwitz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2012-10
- **Final completion:** 2014-09
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2014-11-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00276575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00276575, "Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00276575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*